Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.

@article{Wolowacz2009EfficacyAS,
  title={Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.},
  author={Sorrel E. Wolowacz and Neil S. Roskell and Jonathan M. Plumb and Joseph A. Caprini and Bengt Eriksson},
  journal={Thrombosis and haemostasis},
  year={2009},
  volume={101 1},
  pages={77-85}
}
Dabigatran etexilate has been investigated in three phase III trials for the prevention of venous thromboembolism (VTE). Health technology assessment agencies increasingly require meta-analyses of all relevant evidence for an intervention, if appropriate. The objective of this study was to perform a meta-analysis of efficacy and safety data for the recommended dose of dabigatran etexilate, 220 mg once daily (od), for VTE prophylaxis after total knee arthroplasty (TKA) and total hip arthroplasty… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 70 extracted citations

Determinazione dei farmaci anticoagulanti orali diretti in regime di urgenza

La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine • 2015

Similar Papers

Loading similar papers…